Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JTM104 vs Juvederm in Moderate to Severe Nasolabial Folds
NCT07265791Active, not recruiting
- Sponsor
- JETEMA Co., Ltd.
- Start
- Jan 2026
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in nasolabial folds (2 arms), sponsored by JETEMA Co., Ltd. Primary endpoints: Adverse Events, Serious Adverse Events and 1 more. Started Jan 2026; status: active, not recruiting.
02
Conditions
nasolabial folds
Beyond the preview
Go deeper on NCT07265791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07265791.